This negative impact on the transcriptional pathways regulated by the three most critical drivers of prostate cancer -AR, MYC, and AKT24, was also reflected in the phenotypic response of the LCMT1 expressing cells in both proliferation and long-term colony formation assays as well as in their increased sensitivity to enzalutamide treatment (Supplementary Fig. 5f–g). This evidence concerns the gene AR and prostate carcinoma.